Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials

Clinical Neuropharmacology

Volumn 32, Issue 2, 2009, Pages 97-102

  Gunzler, Steven A ^a,b,d   Pavel, Misha ^c   Koudelka, Caroline ^b   Carlson, Nichole E ^b   Nutt, John G ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Apomorphine; Finger tapping; Foot tapping; Motor fluctuation; Parkinson disease

Indexed keywords

APOMORPHINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INFUSION; DRUG MEGADOSE; FEMALE; FINGER; FOOT; GAIT; HUMAN; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; OUTPATIENT; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SINGLE BLIND PROCEDURE; TECHNIQUE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDITY;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOOT; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MOVEMENT; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; STATISTICS AS TOPIC;

EID: 67749110196     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181684c22     Document Type: Article

References (19)

1. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988;38: 1553-1557.
2. Merrello M, Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. JNeurol Neurosurg Psychiatry 1992;55: 1024-1026.
3. Richards M, Marder K, Cote L, et al. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91.
4. Metman LV, Myre B, Verwey N, et al. Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: an argument against multiple baseline assessments. Mov Disord 2004;19:1079-1084.
5. Gancher ST, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992;52: 504-510.
6. Nutt JG, Carter JH. Apomorphine can sustain the long-duration response to L-dopa in fluctuating PD. Neurology 2000;54:247-250.
7. Gancher ST, Nutt JG. Diurnal responsiveness to apomorphine. Neurology 1987;37:1250-1253.
8. Gancher ST, Woodward WR, Gliessman P, et al. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in Parkinsonism. Ann Neurol 1990;27: 660-665.
9. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991;6:212-216.
10. Morris S, Morris ME. Reliability of measurements obtained with the timed "up and go" test in people with Parkinson disease. Phys Ther 2001;81:810-818.
11. Ball KK, Roenker DL, Wadley VG, et al. Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc 2006;54:77-84.
12. Reid MC, Williams CS, Gill TM. Back pain and decline in lower extremity physical function among community-dwelling older persons. J Gerontol A Biol Sci Med Sci 2005;60A:793-797.
13. Gunzler SA, Koudelka C, Carlson NE, et al. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol. 2008;65:193-198.
14. Martinez-Martin P, Gil-Nagel A, Morlan Gracia L, et al. Unified Parkinson's disease rating scale characteristics and structure. Mov Disord 1994;9:76-83.
15. VokaerM, Abou AzarN, Zegers de BeylD, etal. Effects of levodopaon upper limb mobility and gait in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:1304-1307.
16. Rosner B. Fundamentals of Biostatistics. 6th ed. Belmont, CA: Thomson-Brooks/Cole; 2006:613-617.
17. 18F]-DOPA Ki. Parkinsonism Relat Disord 2001;7:305-309.
18. Burleigh-Jacobs A, Horak FB, Nutt JG, et al. Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers. Mov Disord 1997;2:206-215.
19. Joebges M, Mrowka M, Schimke N, et al. Three-dimensional computerized analysis of diadochokinetic movements of parkinsonian patients. Acta Neurol Scand 2003;108:415-423.